| Name | Title | Contact Details |
|---|---|---|
Nathan Webb |
Director of Commercial Finance | Profile |
Beth Carreon |
Vice President of Finance | Profile |
Rita Seguin |
Executive Vice President of Human Resources | Profile |
Rita Seguin |
Chief Human Resources Officer | Profile |
Andrea Fraser |
Director of Global Human Resources | Profile |
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.
Vein 360 Specializes in reprocessing Closurefast Ablation Catheters. The Vein 360 team is dedicated to providing cost effective reprocessing services.
Kiel Laboratories, Inc. is a Gainesville, GA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Precision BioLogic is a Dartmouth, NS-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Vishnu Chemicals Limited is a Eatontown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.